InnoCare Announces Achievement of Primary Endpoint in Phase IIb Study of Orelabrutinib for SLE and Approval of Phase III Clinical Trial



Orelabrutinib demonstrated outstanding efficacy and well-tolerated safety profile in patients with SLE who had received 48 weeks of treatment in the phase IIb study. A total of 187 patients were enrolled and randomized (1:1:1) into three groups: orelabrutinib 75 mg once-daily (QD), orelabrutinib 50 mg QD, and placebo. Read More



Source link

  • Related Posts

    Wall Street strategists are divided over valuations

    A version of this post first appeared at TKer.co Wall Street strategists are almost unanimously bullish on the outlook for earnings. for S&P 500 earnings in 2026 range from $300…

    Sunday assorted links

    1. What Stanley Kubrick learned from chess. 2. Claims about Ukraine. 3. Rob Wiblin and Dean Ball podcast on AI.  And ChinaTalk surveys Chinese AI in 2025. 4. Stagnant construction…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Wall Street strategists are divided over valuations

    Wall Street strategists are divided over valuations

    Bondi Beach massacre is what globalizing the intifada looks likes

    TechCrunch Mobility: Rivian’s survival plan involves more than cars

    TechCrunch Mobility: Rivian’s survival plan involves more than cars

    Sunday assorted links

    Sunday assorted links

    Sen. Bill Cassidy says “there’s a deal to be had” on health care after failed Senate votes

    Sen. Bill Cassidy says “there’s a deal to be had” on health care after failed Senate votes

    Fantasy football Week 15 inactives: Status of Rome Odunze, Christian McCaffrey and others

    Fantasy football Week 15 inactives: Status of Rome Odunze, Christian McCaffrey and others